These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8786626)

  • 41. [Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2000--I. Gram-positive bacteria].
    Suzuki Y; Nishinari C; Endo H; Tamura C; Jinbo K; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2002 Apr; 55(2):139-53. PubMed ID: 12071093
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1989). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
    Jpn J Antibiot; 1995 Sep; 48(9):1131-60. PubMed ID: 7474333
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
    Pillar CM; Aranza MK; Shah D; Sahm DF
    J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Survey of sensitivities of clinical isolates to antibacterial agents (annual report)].
    Igari J; Inoue M; Nishino T; Watanabe N; Uehara N; Yoshida H; Imafuku Y; Shibano T; Satou S; Kobayashi I; Takahashi A; Yomoda S; Oguri T; Kumasaka K; Okada J; Hirata Y; Uchida K; Kawaguchi R; Ohtaki Y; Ishigo S; Okamoto E; Murakami E; Matsuoka K; Tokuda K; Saeki H
    Jpn J Antibiot; 1997 Aug; 50(8):683-703. PubMed ID: 9339395
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Antibacterial activities of monobactams against fresh clinical isolates].
    Deguchi K; Yokota N; Koguchi M; Nakane Y; Fukayama S; Nishimura Y; Oda S; Tanaka S; Kato M; Sato K
    Jpn J Antibiot; 1988 Nov; 41(11):1600-22. PubMed ID: 3210297
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative in vitro activity of amoxycillin/clavulanate (augmentin), ceftazidime and ceftriaxone against hospital strains of gram-negative and -positive bacteria.
    Abd-Elalim Eltahawy AT; Khalaf RM
    Chemioterapia; 1988 Apr; 7(2):75-8. PubMed ID: 3293818
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Flomoxef showed excellent in vitro activity against clinically important gram-positive and gram-negative pathogens causing community- and hospital-associated infections.
    Yang Q; Zhang H; Cheng J; Xu Z; Hou X; Xu Y
    Diagn Microbiol Infect Dis; 2015 Apr; 81(4):269-74. PubMed ID: 25641126
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Shigeta S; Takahashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Kaku M; Ooe H; Mochida C
    Jpn J Antibiot; 1998 Feb; 51(2):69-111. PubMed ID: 9575437
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
    Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2002 Feb; 55(1):22-60. PubMed ID: 11977920
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Bactericidal activity of biapenem against various bacteria].
    Hiraishi T; Miyata A; Hara T; Araake M; Ogawa H
    Jpn J Antibiot; 2001 Dec; 54(12):581-95. PubMed ID: 11877858
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
    Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MEN 10700, a new penem antibiotic: in vitro antibacterial activity on clinical isolates.
    Ferrari L; Altamura M; De Luca M; Ceruti T
    Chemotherapy; 2002 Mar; 48(1):15-20. PubMed ID: 11901251
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibacterial properties of BO-2727, a new carbapenem antibiotic.
    Kato Y; Otsuki M; Nishino T
    J Antimicrob Chemother; 1997 Aug; 40(2):195-203. PubMed ID: 9301984
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2001). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Watanabe K; Kobayashi Y; Matsukawa M; Uchida H; Kunishima Y; Hirose T; Matsuda S; Sato S; Shigeta S; Fujime M; Fujita K; Yamaguti O; Ogihara M; Ishibashi K; Igari J; Takahashi K; Oguri T; Yoshida H; Imafuku Y; Yamaguchi K; Furuya N; Kashitani F; Murai M; Ooe H; Nishikawa M; Kumon H; Monden K; Oka T; Kitamura M; Kohno S; Tomono K; Miyazaki Y; Matsuoka Y; Fukuhara Y; Hirakata Y; Aoki S
    Jpn J Antibiot; 2003 Oct; 56(5):396-423. PubMed ID: 14692378
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
    Aktaş Z; Kayacan C; Oncul O
    Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates.
    Testa R; Cantón R; Giani T; Morosini MI; Nichols WW; Seifert H; Stefanik D; Rossolini GM; Nordmann P
    Int J Antimicrob Agents; 2015 Jun; 45(6):641-6. PubMed ID: 25748553
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study.
    Walkty A; Adam HJ; Laverdière M; Karlowsky JA; Hoban DJ; Zhanel GG;
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):348-55. PubMed ID: 21353964
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2003). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Matsukawa M; Kunishima Y; Watanabe K; Kobayashi Y; Uchida H; Matsuda S; Hirose T; Sato S; Shigeta S; Fujime M; Fujita K; Yamaguti O; Ishibashi K; Igari J; Suzutani T; Oguri T; Yoshida H; Imafuku Y; Yamaguchi K; Furuya N; Murai M; Deguchi T; Ishihara S; Ooe H; Matsumoto T; Takahashi K; Nishikawa M; Naito S; Egashira T; Konishi T; Oka T; Kitamura M; Kohno S; Fukuhara Y; Hirakata Y; Kondo A; Matsuda J; Nakano M; Kamidono S; Suzuki Y; Arakawa S; Kumon H; Monden K
    Jpn J Antibiot; 2005 Dec; 58(6):518-43. PubMed ID: 16521344
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2001--I. Gram-positive bacteria].
    Suzuki Y; Nishinari C; Endo H; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2003 Aug; 56(4):294-308. PubMed ID: 14567254
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1987). I. Susceptibility distribution].
    Kosakai N; Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Yoshida H; Ogata M; Tazaki H
    Jpn J Antibiot; 1990 Jun; 43(6):919-53. PubMed ID: 2122040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.